Regeneron high-dose Eylea gains FDA approval (NASDAQ:REGN)

FDA APPROVED text on sticker on the blue background with pen and keyboard


FDA APPROVED text on sticker on the blue background with pen and keyboard

Iryna Drozd

The US FDA has approved Regeneron Pharmaceuticals’ (NASDAQ:REGN) high-dose (“HD”) version of its blockbuster therapy Eylea (aflibercept).

The new formulation allows patients to receive treatment less frequently. HD Eylea is dosed every 4 weeks for the first 3 months, then every 8

Leave a Reply

Your email address will not be published. Required fields are marked *